EWTX Earnings & Financial Statements
Edgewise Therapeutics, Inc.
$38.10
+$1.08(+2.92%)
41
Overall
60
Value
30
Tech
34
Quality
Market Cap
$4.02B
Volume
168.09K
52W Range
$14.25 - $48.51
Target Price
$52.62
EWTX earnings and financial statements: Edgewise Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
EWTX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating income | -$191.41M | -$158.83M | -$114.36M | -$71.66M | -$43.22M |
| EBITDA | -$165.51M | -$131.49M | -$98.38M | -$71.12M | -$42.51M |
| Net income | -$167.79M | -$133.81M | -$100.16M | -$67.64M | -$42.81M |
| EPS (diluted) | $-1.63 | $-1.45 | $-1.57 | $-1.26 | $-1.14 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $552.60M | $486.82M | $340.04M | $367.10M | $285.23M |
| Total liabilities | $30.35M | $27.60M | $21.20M | $20.39M | $10.85M |
| Shareholders’ equity | $522.26M | $459.22M | $318.83M | $346.72M | $274.38M |
| Cash and equivalents | $61.15M | $41.67M | $86.10M | $21.99M | $15.57M |
| Long-term debt | $2.98M | $3.74M | $4.43M | $3.80M | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$143.82M | -$109.03M | -$91.95M | -$52.63M | -$33.51M |
| Capital expenditure | -$256.0K | -$1.31M | -$5.75M | -$5.55M | -$668.0K |
| Free cash flow | -$144.07M | -$110.34M | -$97.69M | -$58.18M | -$34.17M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | EWTX | $38.10 | +2.9% | 168.09K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Edgewise Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW